We are live on ! Find out more
RCM

RA Capital Management Portfolio holdings

AUM $9.44B
1-Year Est. Return 157.3%
This Fund
S&P 500
This Quarter Est. Return
-14.03%
1 Year Est. Return
+157.3%
3 Year Est. Return
+589.39%
5 Year Est. Return
+654.96%
10 Year Est. Return
+50,915.53%
AUM
$5.99B
AUM Growth
-$1.53B
Cap. Flow
+$245M
Cap. Flow %
4.09%
Top 10 Hldgs %
62.92%
Holding
100
New
11
Increased
14
Reduced
4
Closed
15

Top Buys

Rank Stock Value
1
PCVX icon
Vaxcyte
PCVX
+$280M
2
SION
Sionna Therapeutics
SION
+$171M
3
IRON icon
Disc Medicine
IRON
+$87.7M
4
GERN icon
Geron
GERN
+$74M
5
ETNB
89bio
ETNB
+$50M

Top Sells

Rank Stock Value
1
LEGN icon
Legend Biotech
LEGN
+$244M
2
XBI icon
State Street SPDR S&P Biotech ETF
XBI
+$111M
3
AXSM icon
Axsome Therapeutics
AXSM
+$84.6M
4
VRNA
Verona Pharma
VRNA
+$82.1M
5
PRAX icon
Praxis Precision Medicines
PRAX
+$58.6M

Sector Composition

Rank Sector Weight
1 Healthcare 99.82%
2 Financials 0.13%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ACET icon
76
Adicet Bio
ACET
$73.6M
$5.69M 0.1%
471,313
– –
HUMA icon
77
Humacyte
HUMA
$186M
$5.65M 0.09%
+3,312,356
New +$12.4M
ZURA icon
78
Zura Bio
ZURA
$537M
$4.15M 0.07%
3,217,503
– –
BIOA
79
BioAge Labs
BIOA
$475M
$3.96M 0.07%
1,052,494
-258,095
-20% -$1.19M
BOLD
80
Boundless Bio
BOLD
$65M
$3.29M 0.06%
2,180,631
– –
NAMSW icon
81
NewAmsterdam Pharma Warrant
NAMSW
$73.6M
$3M 0.05%
333,333
– –
STRO icon
82
Sutro Biopharma
STRO
$405M
$2.89M 0.05%
+443,464
New +$6.98M
LXEO icon
83
Lexeo Therapeutics
LXEO
$364M
$1.9M 0.03%
546,554
– –
CTMX icon
84
CytomX Therapeutics
CTMX
$721M
$636K 0.01%
+1,000,000
New +$775K
SCLX icon
85
Scilex Holding
SCLX
$48.2M
$258K ﹤0.01%
29,606
– –
ALLK
86
DELISTED
Allakos
ALLK
– –
-1,129,931
Closed -$1.37M
ARVN icon
87
Arvinas
ARVN
$550M
– –
-421,348
Closed -$8.08M
AXSM icon
88
Axsome Therapeutics
AXSM
$11B
– –
-1,000,000
Closed -$84.6M
CCCC icon
89
C4 Therapeutics
CCCC
$398M
– –
-4,878,000
Closed -$17.6M
ENTA icon
90
Enanta Pharmaceuticals
ENTA
$384M
– –
-1,038,000
Closed -$5.97M
EVH icon
91
Evolent Health
EVH
$417M
– –
-3,577,197
Closed -$40.2M
LEGN icon
92
Legend Biotech
LEGN
$3.74B
– –
-7,506,934
Closed -$244M
PLRX icon
93
Pliant Therapeutics
PLRX
$65.6M
– –
-1,281,000
Closed -$16.9M
PRAX icon
94
Praxis Precision Medicines
PRAX
$10.3B
– –
-761,955
Closed -$58.6M
RGLS
95
DELISTED
Regulus Therapeutics
RGLS
– –
-336,843
Closed -$532K
RXRX icon
96
Recursion Pharmaceuticals
RXRX
$1.68B
– –
-7,725,096
Closed -$52.2M
THRD
97
DELISTED
Third Harmonic Bio
THRD
– –
-960,620
Closed -$9.88M
VRNA
98
DELISTED
Verona Pharma
VRNA
– –
-1,766,830
Closed -$82.1M
XBI icon
99
State Street SPDR S&P Biotech ETF
XBI
$10B
– –
-1,228,240
Closed -$111M
CMRX
100
DELISTED
Chimerix, Inc.
CMRX
– –
-8,800,000
Closed -$30.6M
1 2 3
4

Similar funds

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
SIM
SRS Investment Management New York $9.47B AUM 60.12% 1-Year Est. Return
NPT
National Philanthropic Trust Jenkintown, Pennsylvania $9.38B AUM 33.37% 1-Year Est. Return
AC
Allstate Corporation Northbrook, Illinois $9.35B AUM 16.13% 1-Year Est. Return
PVI
Partners Value Investments Hamilton, Bermuda $9.34B AUM 12.2% 1-Year Est. Return
WPL
WINDACRE PARTNERSHIP LLC Houston, Texas $9.34B AUM 17.41% 1-Year Est. Return
BAMF
BI Asset Management Fondsmaeglerselskab Kobenhavn, Denmark $9.55B AUM 31.94% 1-Year Est. Return
IAA
Independent Advisor Alliance Charlotte, North Carolina $9.32B AUM 33.19% 1-Year Est. Return

RA Capital Management's Q1 2025 Portfolio in Review

As of Q1 2025, RA Capital Management held 100 positions worth $5.99B, down 20% from $7.51B the previous quarter. Its ten largest holdings account for 63% of the portfolio.

RA Capital Management deployed $245M of net new capital in Q1 2025, opening 11 new positions and adding to 14 existing holdings. Its largest new stake was Sionna Therapeutics: 10,445,322 shares worth $109M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 98% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was 10x Genomics, an estimated $16.8M trimmed.

  • RA Capital Management's largest Q1 2025 buy was Sionna Therapeutics: 10,445,322 shares worth $109M.
  • RA Capital Management added most to Vaxcyte in Q1 2025, an estimated $280M increase.
  • RA Capital Management's biggest Q1 2025 reduction was 10x Genomics, cutting an estimated $16.8M.
  • RA Capital Management fully exited Legend Biotech in Q1 2025, selling an estimated $244M.
  • RA Capital Management's ten largest holdings make up 63% of its $5.99B portfolio in Q1 2025.
  • RA Capital Management opened 11 new positions and closed 15 in Q1 2025.
  • RA Capital Management's portfolio value fell 20% quarter-over-quarter to $5.99B.

Based on RA Capital Management's 13F filing for Q1 2025, filed 15 May 2025.